The scale of infections has led to predictions of very high sales for the first RSV vaccines to reach the market, with analysts at SVB Leerink predicting the market could reach upwards of $10 ...

Analysts at SVB Leerink said that while the offer is fair at that price, Alexion is a “scarce and high-quality asset,” which could prompt an offer from another company. In the past ...

Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $1.28 per share for the year, down from their previous forecast of $1.45. The consensus estimate for Envista’s ...

Leerink Partners analyst Michael Cherny reiterated a Hold rating on Certara (CERT – Research Report) on April 11. The company’s shares closed last Friday at $12.91. Discover outperforming ...

Leerink analyst Faisal Khurshid lowered the firm’s price target on Ironwood (IRWD) to $1 from $3 and keeps a Market Perform rating on the shares after the company announced they will need to run ...

Leerink Partners heeft maandag een update uitgebracht over het aandeel Ironwood Pharmaceuticals (NASDAQ:IRWD) waarbij het koersdoel werd verlaagd van $ 3,00 naar $ 1,00, met behoud van het Market ...

Leerink Partners heeft maandag zijn Market Perform-rating voor het Pfizer-aandeel (NYSE:PFE) gehandhaafd en het koersdoel onveranderd gelaten op $ 28,00. Het aandeel, dat momenteel op $ 21,92 noteert, ...